Compare OVBC & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVBC | VYGR |
|---|---|---|
| Founded | 1872 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.9M | 203.6M |
| IPO Year | 1996 | 2015 |
| Metric | OVBC | VYGR |
|---|---|---|
| Price | $44.71 | $3.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 34.6K | ★ 466.4K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | ★ 1.53 | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | $34.04 |
| Revenue Next Year | N/A | $7.92 |
| P/E Ratio | $29.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.18 | $2.94 |
| 52 Week High | $51.25 | $5.55 |
| Indicator | OVBC | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 58.55 | 62.99 |
| Support Level | $44.63 | $3.29 |
| Resistance Level | $47.12 | $4.31 |
| Average True Range (ATR) | 1.29 | 0.15 |
| MACD | 0.16 | 0.05 |
| Stochastic Oscillator | 75.52 | 93.88 |
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services in Southeastern Ohio and western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers, and other standard banking products and services.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.